Live broadcast time: March 25, 2024 19:00-20:00

content outline:

** Theme 1:** Nonclinical efficacy evaluation of androgenic alopecia treatment drugs

1. Causes and pathogenesis of androgenic hair loss

2. Introduction of commonly used drugs for androgenic hair loss

3. Case analysis of non-clinical pharmacodynamic evaluation

** Theme 2:** Mouse skin hair follicle staging and case sharing

1. Introduction to skin follicle histology and staging

2. Introduction to androgenic hair loss model

3. Case sharing and literature sharing

Lecturer introduced Zhu Zhenna

Special Director of Tiancheng New Drug Evaluation and Pharmacodynamics Research Center

He has been engaged in non-clinical safety evaluation and pharmacodynamic research for 13 years. As the topic leader, he has completed non-clinical research projects on multiple new drugs and participated in the completion of research work on multiple major national science and technology projects. Currently, it mainly focuses on pharmacodynamic evaluation research in the fields of immunity and metabolism.

Yu Jia

Special leader of Tiancheng New Drug Evaluation Clinical Inspection Pathology Center

He graduated from the Department of Animal Medicine of Southwest University with a bachelor's degree and graduated from the Department of Basic Veterinary Medicine of Northeast Agricultural University with a postgraduate degree. He has been engaged in non-clinical pathology research for 5 years and has completed more than 30 non-clinical pathology research projects as the project leader.

Registration/viewing method： Poke me to sign up

Computer viewing link **: https://dx5.cn/4veBhV**(Copy the link to the browser to open) Scan the code and add Yaodu assistant to enter the communication group:

About Tiancheng New Drug Evaluation

Tianjin Tiancheng New Drug Evaluation Co., Ltd.(formerly Tianjin Pharmaceutical Research Institute New Drug Evaluation Co., Ltd.) was established in 2005. It is a wholly-owned subsidiary of China Merchants Group Tianjin Pharmaceutical Research Institute. It focuses on pre-clinical drug research services. It inherits from the original Beijing Institute of Medical Engineering, Tianjin Institute of Medical Engineering, and Tianjin Institute of Traditional Chinese Medicine. The pharmacological and toxicological research teams of the three major scientific research institutions of Tianjin Institute of Traditional Chinese Medicine bring together the three national-level technical platforms of innovative drug pharmacodynamics, pharmacokinetics, and toxicology. It is the earliest pre-clinical CRO for full-disciplinary evaluation in China.

The company has nine GLP certifications from the State Food and Drug Administration and international AAALAC certification. It has served more than 400 domestic and foreign companies, cooperated with nearly 50 scientific research colleges, and has completed more than 1400 pre-clinical research projects and helped obtain more than 100 clinical approvals, including multiple Sino-US double reporting projects. service scope covers:

Early pharmaceutical research:

• In vitro pharmacodynamic study:Cell lines, isolated organs, etc.;

• In vitro pharmacokinetic studies:Plasma protein binding, metabolic stability, metabolite identification, metabolic enzymes, transporters, etc.;

• Early toxicity studies:hERG, genetic virus, etc.

Preclinical evaluation of drugs:

• Systematic evaluation of preclinical disciplines such as pharmacodynamics, pharmacokinetics, and toxicology;

• Scheme design, evaluation research, report writing, review communication, etc.;

• Comply with the registration and application requirements of NMPA, FDA, etc.

Empowering the entire pharmaceutical industry chain:

• Project establishment research, market consultation, capital operation, MAH services, etc.